Cite
Tornatore L, Capece D, D'Andrea D, et al. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3. Toxicol Rep. 2019;6:369-379doi: 10.1016/j.toxrep.2019.04.006.
Tornatore, L., Capece, D., D'Andrea, D., Begalli, F., Verzella, D., Bennett, J., Acton, G., Campbell, E. A., Kelly, J., Tarbit, M., Adams, N., Bannoo, S., Leonardi, A., Sandomenico, A., Raimondo, D., Ruvo, M., Chambery, A., Oblak, M., Al-Obaidi, M. J., Kaczmarski, R. S., Gabriel, I., Oakervee, H. E., Kaiser, M. F., Wechalekar, A., Benjamin, R., Apperley, J. F., Auner, H. W., & Franzoso, G. (2019). Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3. Toxicology reports, 6369-379. https://doi.org/10.1016/j.toxrep.2019.04.006
Tornatore, Laura, et al. "Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3." Toxicology reports vol. 6 (2019): 369-379. doi: https://doi.org/10.1016/j.toxrep.2019.04.006
Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3. Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019. PMID: 31080744; PMCID: PMC6502747.
Copy
Download .nbib